Hospital
Plantation General Hospital L P
Plantation General Hospital L P was paid $7.72M by Medicaid between Jan 2018 and Nov 2021, across 193 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoPLANTATION GENERAL HOSPITAL L P
PLANTATION, FL 33317
PLANTATION, FL 33317
33aNPI1144274317assigned 05/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.72M
24GClaims489,019
24DCodes billed193
24AFirst – last monthJan 2018 – Nov 2021
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#63 of 163
Median peer was paid$4.77M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,297 | $694K | |
| 2019 | 186,123 | $1.99M | |
| 2020 | 120,493 | $1.56M | |
| 2021 | 136,106 | $3.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 40,612 | 37,392 | $1.38M |
| 80053 | Comprehensive metabolic panel | 14% | 21,053 | 17,869 | $1.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 26,344 | 22,827 | $927K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 6,531 | 6,152 | $287K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 4,409 | 4,001 | $286K |
| 87070 | 3.4% | 11,277 | 10,841 | $260K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.3% | 2,083 | 1,926 | $176K |
| A9270 | Non-covered item or service | 2.1% | 6,531 | 1,465 | $164K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 987 | 898 | $157K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 5,518 | 4,699 | $151K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 4,614 | 3,740 | $144K |
| 81025 | 1.7% | 13,301 | 12,039 | $130K |
181 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.6% | 1,373 | $121K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.5% | 10,278 | $119K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.5% | 1,995 | $115K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 7,342 | $107K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 1,161 | $106K |
| 87275 | 1.3% | 13,003 | $103K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,568 | $100K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 540 | $91K |
| G0378 | Hospital observation service, per hour | 1.2% | 7,287 | $91K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.0% | 1,615 | $78K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 645 | $71K |
| 84702 | <1% | 5,144 | $67K | |
| J3490 | Unclassified drugs | <1% | 728 | $61K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,576 | $60K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,665 | $57K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,982 | $57K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,814 | $52K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 948 | $51K |
| 81003 | <1% | 7,432 | $46K | |
| 74018 | <1% | 2,668 | $45K | |
| 80047 | <1% | 2,041 | $42K | |
| 76801 | <1% | 3,492 | $41K | |
| 85027 | <1% | 28,562 | $35K | |
| S5010 | 5% dextrose and 0.45% normal saline, 1000 ml | <1% | 103 | $35K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,733 | $32K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,537 | $32K |
| 87480 | <1% | 1,200 | $30K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,014 | $27K |
| 87077 | <1% | 2,147 | $27K | |
| 12011 | <1% | 411 | $25K | |
| 87807 | <1% | 4,603 | $25K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,207 | $24K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,645 | $24K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 552 | $23K |
| 86850 | <1% | 1,297 | $22K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,160 | $22K |
| 87040 | <1% | 4,774 | $21K | |
| 81001 | <1% | 4,490 | $20K | |
| 73562 | <1% | 1,244 | $19K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 509 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,648 | $19K |
| 84703 | <1% | 7,653 | $17K | |
| 93976 | <1% | 1,312 | $16K | |
| 73610 | <1% | 815 | $15K | |
| 84112 | <1% | 126 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 834 | $14K |
| 93971 | <1% | 494 | $14K | |
| 84484 | <1% | 7,221 | $14K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 368 | $13K |
| 87487 | <1% | 1,739 | $13K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 151 | $13K |
| 73110 | <1% | 554 | $12K | |
| 73630 | <1% | 846 | $12K | |
| 70491 | <1% | 32 | $11K | |
| 73140 | <1% | 375 | $10K | |
| 93970 | <1% | 266 | $10K | |
| 83880 | <1% | 1,536 | $10K | |
| 74022 | <1% | 750 | $10K | |
| 82550 | <1% | 4,035 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 674 | $10K |
| 73130 | <1% | 627 | $10K | |
| 72100 | <1% | 1,054 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,807 | $9K |
| 73030 | <1% | 585 | $8K | |
| 12001 | <1% | 221 | $8K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,345 | $8K |
| 74019 | <1% | 323 | $8K | |
| 78580 | <1% | 37 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,780 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 195 | $7K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,474 | $6K |
| 86900 | <1% | 2,879 | $6K | |
| 82553 | <1% | 1,729 | $5K | |
| 83690 | <1% | 6,301 | $5K | |
| 85610 | <1% | 4,460 | $5K | |
| 76775 | <1% | 141 | $5K | |
| 85730 | <1% | 4,104 | $5K | |
| 10060 | <1% | 90 | $4K | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 50 | $4K |
| 87205 | <1% | 563 | $4K | |
| 94644 | <1% | 820 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 490 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,172 | $3K |
| 83605 | <1% | 1,953 | $3K | |
| 70486 | <1% | 193 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,270 | $2K |
| 72040 | <1% | 243 | $2K | |
| 12002 | <1% | 40 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,427 | $2K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 97 | $2K |
| 95819 | <1% | 123 | $2K | |
| 73590 | <1% | 210 | $2K | |
| 86140 | <1% | 3,864 | $2K | |
| 73080 | <1% | 144 | $2K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $2K |
| 80076 | <1% | 901 | $2K | |
| 73090 | <1% | 84 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,946 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,980 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,045 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,734 | $1K |
| 97163 | <1% | 38 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,694 | $1K |
| 86738 | <1% | 890 | $1K | |
| 83735 | <1% | 1,032 | $1K | |
| 85007 | <1% | 1,081 | $992.85 | |
| 73502 | <1% | 178 | $955.11 | |
| 87510 | <1% | 1,186 | $947.16 | |
| 87660 | <1% | 1,185 | $850.74 | |
| 87276 | <1% | 13,000 | $803.15 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,118 | $795.99 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,143 | $783.14 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,388 | $773.12 |
| 93017 | <1% | 32 | $645.49 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,318 | $617.06 |
| 85379 | <1% | 1,454 | $604.05 | |
| 94760 | <1% | 181 | $464.90 | |
| 86901 | <1% | 2,320 | $449.82 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $422.09 |
| 97116 | <1% | 50 | $390.57 | |
| 82272 | <1% | 16 | $386.27 | |
| 82803 | <1% | 133 | $374.47 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,714 | $364.98 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 722 | $305.48 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,097 | $289.31 |
| 82247 | <1% | 128 | $284.38 | |
| 85651 | <1% | 1,171 | $267.84 | |
| 86308 | <1% | 40 | $255.15 | |
| 82150 | <1% | 866 | $249.38 | |
| 73660 | <1% | 13 | $205.48 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 858 | $202.02 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,005 | $184.02 |
| 80320 | <1% | 488 | $133.12 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 391 | $130.29 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 452 | $129.59 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 256 | $125.51 |
| 36600 | <1% | 59 | $102.74 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 62 | $102.74 |
| 76870 | <1% | 14 | $98.16 | |
| 86780 | <1% | 12 | $78.35 | |
| 80061 | Lipid panel | <1% | 193 | $55.64 |
| 90714 | <1% | 550 | $43.43 | |
| 87147 | <1% | 278 | $35.99 | |
| 96376 | <1% | 302 | $34.04 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 202 | $23.77 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 279 | $21.63 |
| 82248 | <1% | 16 | $8.08 | |
| 80177 | <1% | 28 | $4.24 | |
| 82040 | <1% | 88 | $3.33 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 29 | $3.31 |
| 82009 | <1% | 264 | $3.01 | |
| 84460 | <1% | 90 | $1.66 | |
| 84155 | <1% | 88 | $1.66 | |
| 84450 | <1% | 93 | $1.66 | |
| 84075 | <1% | 88 | $1.66 | |
| 87186 | 0% | 446 | $0.00 | |
| 00920 | 0% | 54 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 493 | $0.00 |
| 00300 | 0% | 59 | $0.00 | |
| 84100 | 0% | 92 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 13 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 83 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 16 | $0.00 |
| 85384 | 0% | 15 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 37 | $0.00 |
| 72070 | 0% | 35 | $0.00 | |
| 84550 | 0% | 16 | $0.00 | |
| 85014 | 0% | 16 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 293 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 478 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,353 | $0.00 |
| 76820 | 0% | 20 | $0.00 | |
| 82077 | 0% | 272 | $0.00 | |
| 88304 | 0% | 137 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 31 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 831 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 70 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 44 | $0.00 |
| 83615 | 0% | 14 | $0.00 | |
| 85018 | 0% | 16 | $0.00 | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUGHES, DAVID (CFO)
| Provider | Location | Paid |
|---|---|---|
| Lakeshore Community Health Care, INC | Sheboygan, WI | $14.74M |
| Lakeshore Community Health Care, INC | Manitowoc, WI | $9.21M |
| Cornerstone Prosthetics and Orthotics, INC | Everett, WA | $1.54M |
| General Physician Sub I PLLC | Medina, NY | $249K |
| Reliable Medical Response, LLC | Brandon, FL | $75K |
| Geriatric Essentials, PC | Dyersburg, TN | $55K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.